Genelux Corporation (GNLX)
2.50
-0.04 (-1.57%)
At close: Apr 03, 2025, 3:59 PM
2.37
-5.20%
After-hours: Apr 03, 2025, 04:24 PM EDT
Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation
| Country | United States |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Thomas Zindrick J.D. |
Contact Details
Address: 2625 Townsgate Road Westlake Village, California United States | |
| Website | https://www.genelux.com |
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001231457 |
| CUSIP Number | |
| ISIN Number | US36870H1032 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Zindrick J.D. | Chairman, Chief Executive Officer & President |
| Matthew Pulisic M.B.A. | Chief Financial Officer and Principal Financial & Accounting Officer |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer |
| Ralph Smalling B.Sc. | Vice President & Head of Regulatory Affairs |
| Sean Ryder J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | S-8 | Filing |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 424B5 | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 25, 2025 | FWP | Filing |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 03, 2025 | 4 | Filing |
| Feb 03, 2025 | 3 | Filing |
| Feb 03, 2025 | 8-K | Current Report |
| Dec 31, 2024 | 4/A | [Amend] Filing |